Needham & Company
View Older Stories
-
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Arena Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference on April 14
-
Companies with NDRs 08/28
-
Arena Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 10
-
Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27
-
Needham & Company Upgrades Arena Pharma (ARNA) to Buy
-
Arena Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference on April 4th
-
Needham & Company Reiterates Hold on Arena Pharma (ARNA) Following Revised Belviq Agreement
-
Pre-Open Stock Movers 04/12: (FOLD) (ARNA) (HLX) Higher; (HZNP) (OZM) (JNPR) Lower (more...)
-
Needham & Company Updates Ests on Arena Pharma (ARNA) Following Q3 Results; Maintains 'Hold' Rating
-
Arena Pharmaceuticals to Present at the Annual Needham Healthcare Conference
-
Unusual 11 Mid-Day Movers 9/18: (EMKR) (VVUS) (XXII) Higher; (MCHX) (VHC) (ECTE) Lower
-
Arena Pharma (ARNA) Belviq Numbers Lowered at Needham & Company
-
Needham & Company Cautious on Arena Pharma (ARNA) Into Q3
-
VIVUS (VVUS) to Report Q1 Results May 8th; Focus on Promotions vs. New Rx
-
Needham Sees Strong Start for Arena's (ARNA) Belviq in U.S.; European Approval Unlikely
-
StreetInsider.com Pre-Open Movers 01/22: (ATNI) (BOX) (RIMM) Higher; (ARNA) (NUS) (FTNT) Lower (more...)
-
Notable Analyst Rating Changes 09/06: (AKS) (ATVI) (GOLD) Upgraded; (NOK) (CLF) (OCZ) Downgraded
-
Needham & Company on Arena Pharma (ARNA); Obese Population Large, But Poor Track Record of Drugs in the Space
-
Notable Analyst Rating Changes 06/25: (NFLX) (NVDA) (SNDK) Upgraded; (ARNA) (RIMM) (AN) Downgraded
-
Needham Maintains Cautious View of Arena Pharma (ARNA)
-
Notable Analyst Rating Changes 05/09: (STJ) (ARNA) (UA) Upgraded; (AET) (MRVL) (HLF) Downgraded
-
Needham & Company Maintains a 'Hold' on Arena Pharma (ARNA); Meaningful Risks to Lorcaserin Approval
-
Needham & Company Remains Cautious on Arena Pharma (ARNA) Given Lingering Uncertainty Around Rat Mammary Tumors; Lorcaserin NDA Resubmitted
-
Needham & Company Maintains a 'Hold' on Arena Pharma (ARNA); Remain Cautious on the Stock
-
Unusual 11 Mid-Day Movers 07/16: LSBX, ARNA, AVII, CYPB, SCHW, TSLA Higher; VVUS, JST, ROIAK, OREX, PLCM Lower
-
Notable Analyst Rating Changes 07/16: GS, JPM, ARNA, ADM Upgraded; VVUS, BP, RBA, OREX Downgraded
-
Morning Movers 7/16: LSBX, ARNA, AVII Higher; VVUS, JST, VRNM, BIOF, VIDE, PLCM Lower
-
Notable Analyst Rating Changes 12/17: NWSA, UNM, LNC, PTV Upgraded; ADP, AEM, FGXI, OC Downgrades
-
Needham Downgrades Arena Pharmaceuticals (ARNA) to Hold